Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma

Cabozantinib is an oral multikinase inhibitor whose targets include vascular endothelial growth factor receptors, MET, and the TAM family of kinases (TYRO3, AXL, MER). Cabozantinib is approved for patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib, based...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Gabriel, Darling, Julianne O., Mindo, Malori, Damicis, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Therapy in Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434721/
https://www.ncbi.nlm.nih.gov/pubmed/32770441
http://dx.doi.org/10.1007/s11523-020-00736-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434721/
https://www.ncbi.nlm.nih.gov/pubmed/32770441
http://dx.doi.org/10.1007/s11523-020-00736-8

Ejemplares similares